Use of Nintedanib and Pirfenidone in Non–Idiopathic Pulmonary Fibrosis Lung Disease

The use of the medications nintedanib and pirfenidone has become routine for management of idiopathic pulmonary fibrosis (IPF). However, their use in non-IPF lung disease, including other interstitial lung diseases (ILD) and pulmonary malignancies, is still being investigated. A review of the uses o...

Full description

Saved in:
Bibliographic Details
Published in:American journal of respiratory and critical care medicine 2021-07, Vol.204 (1), p.92-94
Main Authors: Warrior, Krishnan, Chung, Paul A., Reid, Michal, Bemiss, Bradford C.
Format: Article
Language:English
Subjects:
Anti-inflammatory agents
Clinical outcomes
Drugs
FDA approval
Inhibitor drugs
Lung diseases
Patient safety
Pulmonary fibrosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of the medications nintedanib and pirfenidone has become routine for management of idiopathic pulmonary fibrosis (IPF). However, their use in non-IPF lung disease, including other interstitial lung diseases (ILD) and pulmonary malignancies, is still being investigated. A review of the uses of pirtenidone and nintedanib for pulmonary diseases other than IFF is offered. In the first review, the INBUILD (Efficacy and Safety of Nintedanib in Patient) with Progressive Fibrosing Interstitial Lung Disease [PF-ILDJ) trial by Flaherty and colleagues has provided rationale for the use of nintedanib in progressive fibrosing ILDs besides nintedanib, resulting in approval from the US Food and Drug Administration for this purpose. The second review shows some promise for the use of pirfenidone in unclassifiable ILDs, necessitating further study. The final study reviewed examined the use of nintedanib as an adjunctive antiangiogenic agent in malignant mesothelioma but unfortunately demonstrated no survival benefits.
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.202012-4356RR